Skip to content

Effect of Intravenous Dexmedetomidine Infusion on Postoperative Pain in Total Knee Arthroplasty Patients with Different Pain Sensitivities: A Clinical Study

Effect of Intravenous Dexmedetomidine Infusion on Postoperative Pain in Total Knee Arthroplasty Patients with Different Pain Sensitivities: A Clinical Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117753
Enrollment
Unknown
Registered
2026-01-28
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

High pain sensitivity / dexmedetomidine group:At the induction of anesthesia, a loading dose of dexmedetomidine 1 µg/kg will be administered by intravenous infusion over 10 minutes, followed by a cont
High Pain Sensitivity/Saline Group:At the induction of anesthesia, a loading dose of normal saline, identical in appearance, volume, and infusion rate to the study drug, will be intravenously infused
Low pain sensitivity / dexmedetomidine group:At the induction of anesthesia, a loading dose of dexmedetomidine 1 µg/kg will be administered by intravenous infusion over 10 minutes, followed by a conti
Low Pain Sensitivity/Saline Group:At the induction of anesthesia, a loading dose of normal saline, identical in appearance, volume, and infusion rate to the study drug, will be intravenously infused o

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 75 years who are scheduled to undergo total knee arthroplasty due to osteoarthritis; 2. ASA classification I–II; 3. Completion of PSQ assessment before surgery; 4. Meeting surgical indications, able to tolerate general anesthesia, and will not use a postoperative analgesic pump; 5. Signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of chronic opioid use; 2. Severe cardiovascular dysfunction, such as sick sinus syndrome, second-degree or third-degree atrioventricular block, bradycardia (heart rate <50 bpm); 3. Severe liver and kidney dysfunction (albumin <30 g/L, glomerular filtration rate <30 mL/min/1.73m^2); 4. Individuals with psychiatric disorders who cannot cooperate; 5. Individuals with multiple neuropathies or diabetic neuropathy; 6. Allergic to dexmedetomidine.

Design outcomes

Primary

MeasureTime frame
Pain score at rest;

Secondary

MeasureTime frame
Time to first request for analgesic medication and total analgesic consumption;Pain score during activity;Sedation Score;Sleep Quality;Quality of Recovery Score;Incidence of Adverse Events;

Countries

China

Contacts

Public ContactWu Ping

The First Affiliated Hospital of Dalian Medical University

13684559453@163.com+86 180 9887 6217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026